Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sarepta Therapeutics (NQ: SRPT ) 132.66 +0.96 (+0.73%) Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sarepta Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > 3 Biotech Stocks With the Potential to Make You an Overnight Millionaire May 04, 2024 Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. Via InvestorPlace Exposures Product Safety Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health May 03, 2024 From Sarepta Therapeutics, Inc. Via Business Wire What Analysts Are Saying About Sarepta Therapeutics Stock May 02, 2024 Via Benzinga Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday May 02, 2024 Via Benzinga SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Sarepta Therapeutics: Q4 Earnings Insights February 28, 2024 Via Benzinga A Preview Of Sarepta Therapeutics's Earnings February 27, 2024 Via Benzinga Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript May 01, 2024 SRPT earnings call for the period ending March 31, 2024. Via The Motley Fool Topics Earnings Exposures Financial Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments May 01, 2024 From Sarepta Therapeutics, Inc. Via Business Wire 1 Top Growth Stock to Buy and Hold for 10 Years May 01, 2024 This company's lineup might look very different in a decade, but the end result will be the same for investors. Via The Motley Fool Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 30, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics Stock Shows Improved Technical Strength April 29, 2024 The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. Via Investor's Business Daily Sarepta Therapeutics to Announce First Quarter 2024 Financial Results April 24, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst April 08, 2024 Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming. Via Investor's Business Daily 2 Biotech Stocks to Buy Hand Over Fist in April April 06, 2024 These drugmakers have made important moves over the past year. Via The Motley Fool 10 Health Care Stocks Whale Activity In Today's Session April 04, 2024 Via Benzinga Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 29, 2024 From Sarepta Therapeutics, Inc. Via Business Wire How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback March 28, 2024 The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy. Via Investor's Business Daily Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? March 13, 2024 The threat is still emerging, but it could be significant. Via The Motley Fool This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO March 08, 2024 REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. Via Benzinga Got $1,000? Buy These Hot Growth Stocks Before They Take Off. March 08, 2024 These stocks haven't been able to get much traction lately, even though they clearly deserve to now. Via The Motley Fool Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst March 04, 2024 The upcoming regulatory decision on its latest drug could be big. Via The Motley Fool Sarepta Therapeutics to Present at Upcoming Investor Conferences March 04, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 29, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program February 29, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript February 29, 2024 SRPT earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments February 28, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Is It Too Late to Buy Sarepta Therapeutics Stock? February 28, 2024 The company's hyperfocus on its core area could continue to be highly lucrative. Via The Motley Fool Earnings Scheduled For February 28, 2024 February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. Via Benzinga Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices February 26, 2024 Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.